Abstract
The promyeloctic leukemia protein PML is a tumor suppressor that was originally identified due to its involvement in the (15;17) translocation of acute promyelocytic leukemia. While the majority of early research has focused upon the role of PML in the pathogenesis of leukemia, more recent evidence has identified important roles for PML in tissues outside the hemopoietic system, including the central nervous system (CNS). Here, we review recent literature on the role of PML in the CNS, with particular focus on the processes of neurodevelopment and neurodegeneration, and propose new lines of investigation.
Similar content being viewed by others
References
Grimwade D, Solomon E (1997) Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Curr Top Microbiol Immunol 220:81–112
Melnick A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B et al (1999) Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia 13:1534–1538
Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167–3215
Salomoni P, Pandolfi PP (2002) The role of PML in tumor suppression. Cell 108:165–170
Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L et al (2001) The tripartite motif family identifies cell compartments. EMBO J 20:2140–2151
Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434
Meroni G, Diez-Roux G (2005) TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases. Bioessays 27:1147–1157
Burkhard P, Stetefeld J, Strelkov SV (2001) Coiled coils: a highly versatile protein folding motif. Trends Cell Biol 11:82–88
Borden KL, Boddy MN, Lally J, O'Reilly NJ, Martin S, Howe K et al (1995) The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J 14:1532–1541
Borden KL, Lally JM, Martin SR, O'Reilly NJ, Solomon E, Freemont PS (1996) In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. Proc Natl Acad Sci U S A 93:1601–1606
Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D et al (1998) Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16:2905–2913
Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A et al (2006) Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 66:6192–6198
Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A et al (1992) Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 7:1083–1091
Jensen K, Shiels C, Freemont PS (2001) PML protein isoforms and the RBCC/TRIM motif. Oncogene 20:7223–7233
Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3:799–808
Lin HK, Bergmann S, Pandolfi PP (2004) Cytoplasmic PML function in TGF-beta signalling. Nature 431:205–211
Salomoni P, Bellodi C (2007) New insights into the cytoplasmic function of PML. Histol Histopathol 22:937–946
Condemine W, Takahashi Y, Le Bras M, de The H (2007) A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J Cell Sci 120:3219–3227
Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A (2002) Deconstructing PML-induced premature senescence. EMBO J 21:3358–3369
Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W et al (2000) The function of PML in p53-dependent apoptosis. Nat Cell Biol 2:730–736
Borden KL (2002) Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol 22:5259–5269
Chang KS, Fan YH, Andreeff M, Liu J, Mu ZM (1995) The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 85:3646–3653
Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN et al (1999) SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 112(Pt 3):381–393
Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6:665–672
Yang S, Kuo C, Bisi JE, Kim MK (2002) PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 4:865–870
Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al (1999) PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147:221–234
Zhong S, Salomoni P, Pandolfi PP (2000) The transcriptional role of PML and the nuclear body. Nat Cell Biol 2:E85–E90
Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L et al (1992) A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 101(Pt 4):773–784
Dellaire G, Bazett-Jones DP (2004) PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26:963–977
Boisvert FM, Hendzel MJ, Bazett-Jones DP (2000) Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol 148:283–292
Eskiw CH, Dellaire G, Bazett-Jones DP (2004) Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J Biol Chem 279:9577–9585
Wang J, Shiels C, Sasieni P, Wu PJ, Islam SA, Freemont PS et al (2004) Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. J Cell Biol 164:515–526
Kumar PP, Bischof O, Purbey PK, Notani D, Urlaub H, Dejean A et al (2007) Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. Nat Cell Biol 9:45–56
Shiels C, Islam SA, Vatcheva R, Sasieni P, Sternberg MJ, Freemont PS et al (2001) PML bodies associate specifically with the MHC gene cluster in interphase nuclei. J Cell Sci 114:3705–3716
Ayaydin F, Dasso M (2004) Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell 15:5208–5218
Fu C, Ahmed K, Ding H, Ding X, Lan J, Yang Z et al (2005) Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24:5401–5413
Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET (1998) Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 273:3117–3120
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341–1348
Zhu J, Lallemand-Breitenbach V, de The H (2001) Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257–7265
Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S et al (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18:88–98
Lallemand-Breitenbach V, de The H (2010) PML nuclear bodies. Cold Spring Harb Perspect Biol 2:a000661
Aoto T, Saitoh N, Ichimura T, Niwa H, Nakao M (2006) Nuclear and chromatin reorganization in the MHC-Oct3/4 locus at developmental phases of embryonic stem cell differentiation. Dev Biol 298:354–367
Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R et al (1995) Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood 85:1871–1880
Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B et al (1996) Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 149:2023–2035
Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Henin D et al (1995) PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res 55:1590–1597
Li W, Ferguson BJ, Khaled WT, Tevendale M, Stingl J, Poli V et al (2009) PML depletion disrupts normal mammary gland development and skews the composition of the mammary luminal cell progenitor pool. Proc Natl Acad Sci U S A 106(12):4725–4730
Everett RD, Chelbi-Alix MK (2007) PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819–830
Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, Saib A et al (1995) Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11:2565–2573
Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14:2015–2027
Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207–210
de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G et al (2004) PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13:523–535
Jiang WQ, Zhong ZH, Henson JD, Reddel RR (2007) Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 26:4635–4647
Stagno D’Alcontres M, Mendez-Bermudez A, Foxon JL, Royle NJ, Salomoni P (2007) Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA. J Cell Biol 179:855–867
Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S et al (2010) Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140:678–691
Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD (2010) Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 107:14075–14080
Seeler JS, Marchio A, Sitterlin D, Transy C, Dejean A (1998) Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A 95:7316–7321
He D, Mu ZM, Le X, Hsieh JT, Pong RC, Chung LW et al (1997) Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res 57:1868–1872
Le XF, Yang P, Chang KS (1996) Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J Biol Chem 271:130–135
Mu ZM, Le XF, Vallian S, Glassman AB, Chang KS (1997) Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis 18:2063–2069
Le XF, Vallian S, Mu ZM, Hung MC, Chang KS (1998) Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene 16:1839–1849
Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M et al (1998) The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol 18:1084–1093
Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729–740
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593–602
Regad T, Bellodi C, Nicotera P, Salomoni P (2009) The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci 12:132–140
Bernardi R, Pandolfi PP (2003) Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22:9048–9057
Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H (2004) PML nuclear bodies and apoptosis. Oncogene 23:2819–2824
Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441:523–527
Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20:266–272
Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H (1998) PML induces a novel caspase-independent death process. Nat Genet 20:259–265
Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K et al (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19:6185–6195
Salomoni P, Khelifi AF (2006) Daxx: death or survival protein? Trends Cell Biol 16:97–104
Khelifi AF, D’Alcontres MS, Salomoni P (2005) Daxx is required for stress-induced cell death and JNK activation. Cell Death Differ 12:724–733
Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al (2004) Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96:269–279
Lee HE, Jee CD, Kim MA, Lee HS, Lee YM, Lee BL et al (2007) Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett 247:103–109
Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF et al (2000) Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 85:599–605
Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J et al (1995) The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10:1315–1324
Yoon GS, Yu E (2001) Overexpression of promyelocytic leukemia protein and alteration of PML nuclear bodies in early stage of hepatocarcinogenesis. J Korean Med Sci 16:433–438
Gray PA, Fu H, Luo P, Zhao Q, Yu J, Ferrari A et al (2004) Mouse brain organization revealed through direct genome-scale TF expression analysis. Science 306:2255–2257
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et al (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453(7198):1072–1078
Woulfe J, Gray D, Prichett-Pejic W, Munoz DG, Chretien M (2004) Intranuclear rodlets in the substantia nigra: interactions with marinesco bodies, ubiquitin, and promyelocytic leukemia protein. J Neuropathol Exp Neurol 63:1200–1207
Woulfe JM, Prichett-Pejic W, Rippstein P, Munoz DG (2007) Promyelocytic leukaemia-immunoreactive neuronal intranuclear rodlets in the human brain. Neuropathol Appl Neurobiol 33:56–66
Villagra NT, Navascues J, Casafont I, Val-Bernal JF, Lafarga M, Berciano MT (2006) The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains. Neurobiol Dis 21:181–193
Villagra NT, Berciano J, Altable M, Navascues J, Casafont I, Lafarga M et al (2004) PML bodies in reactive sensory ganglion neurons of the Guillain-Barre syndrome. Neurobiol Dis 16:158–168
Berube NG, Mangelsdorf M, Jagla M, Vanderluit J, Garrick D, Gibbons RJ et al (2005) The chromatin-remodeling protein ATRX is critical for neuronal survival during corticogenesis. J Clin Invest 115:258–267
Ritchie K, Seah C, Moulin J, Isaac C, Dick F, Berube NG (2008) Loss of ATRX leads to chromosome cohesion and congression defects. J Cell Biol 180:315–324
Berube NG, Healy J, Medina CF, Wu S, Hodgson T, Jagla M et al (2007) Patient mutations alter ATRX targeting to PML nuclear bodies. Eur J Hum Genet 16(2):192–201
Salomoni P (2009) Stemming out of a new PML era? Cell Death Differ 16:1083–1092
Milyavsky M, Gan OI, Trottier M, Komosa M, Tabach O, Notta F et al (2010) A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 7:186–197
Schwamborn JC, Berezikov E, Knoblich JA (2009) The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell 136:913–925
Tuoc TC, Stoykova A (2008) Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin-proteosome system. Genes Dev 22:1972–1986
Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL (1999) Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 8:673–682
Kaytor MD, Duvick LA, Skinner PJ, Koob MD, Ranum LP, Orr HT (1999) Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. Hum Mol Genet 8:1657–1664
Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB et al (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41–53
Takahashi J, Fujigasaki H, Iwabuchi K, Bruni AC, Uchihara T, El Hachimi KH et al (2003) PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases. Neurobiol Dis 13:230–237
Takahashi J, Fujigasaki H, Zander C, El Hachimi KH, Stevanin G, Durr A et al (2002) Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content. Brain 125:1534–1543
Yamada M, Sato T, Shimohata T, Hayashi S, Igarashi S, Tsuji S et al (2001) Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases. Am J Pathol 159:1785–1795
Mackenzie IR, Baker M, West G, Woulfe J, Qadi N, Gass J et al (2006) A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain 129:853–867
Kumada S, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T et al (2002) Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies. J Neuropathol Exp Neurol 61:984–991
Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C et al (2008) Huntington’s disease: from pathology and genetics to potential therapies. Biochem J 412:191–209
Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B et al (2006) A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269–283
Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A et al (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193:1361–1371
Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB et al (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328:240–243
Lafarga M, Berciano MT, Pena E, Mayo I, Castano JG, Bohmann D et al (2002) Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol Biol Cell 13:2771–2782
Janer A, Martin E, Muriel MP, Latouche M, Fujigasaki H, Ruberg M et al (2006) PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol 174:65–76
Qin Q, Inatome R, Hotta A, Kojima M, Yamamura H, Hirai H et al (2006) A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein. J Cell Biol 172:497–504
Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M et al (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291:2423–2428
Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97:6763–6768
Hayashi T, Sasaki C, Iwai M, Sato K, Zhang WR, Warita H et al (2001) Induction of PML immunoreactivity in rat brain neurons after transient middle cerebral artery occlusion. Neurol Res 23:772–776
Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C et al (1998) Role of PML in cell growth and the retinoic acid pathway. Science 279:1547–1551
Wichterle H, Przedborski S (2010) What can pluripotent stem cells teach us about neurodegenerative diseases? Nat Neurosci 13:800–804
Pardal R, Ortega-Saenz P, Duran R, Lopez-Barneo J (2007) Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 131:364–377
Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S et al (2005) A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7:143–153
Acknowledgements
We apologize for any omission of references, which was due to space limitations. Laboratory is supported by the Samantha Dickson Brain Tumour Trust and the Wellcome Trust.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salomoni, P., Betts-Henderson, J. The Role of PML in the Nervous System. Mol Neurobiol 43, 114–123 (2011). https://doi.org/10.1007/s12035-010-8156-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-010-8156-y